Joint Venture & License Agreement

This Joint Venture & License Agreement (the "Agreement") is entered into on this 15th day of September, 2025, by and between Avant Technologies Inc. (“AVAI”) and SGAustria Pte. Ltd. (“Austrianova”), collectively referred to as the

"Parties."

WHEREAS, Avant Technologies Inc., a Nevada Corporation trading under the ticker symbol AVAI (Symbol OTCQB: AVAI)(“AVAI”), and SGAustria Pte. Ltd., a Singaporean company with registered number UEN 200901830C (“Austrianova”) entered into a Joint Venture and License Agreement (the “License Agreement”) which will become eXective immediately.

WHEREAS, under the License Agreement, the parties will form a new Nevada Corporation called “Klothonova, Inc.” (“Klothonova”) and contribute the proprietary rights, know-how, resources and funding as described in the License Agreement.

WHEREAS, Austrianova is a cutting-edge Biotech company based in Singapore embracing leading world quality standards to produce cell-based products. Austrianova’s expertise and technologies are backed up by more than 50 international peer reviewed publications, as well as by contracts from leading pharmaceutical and biotech companies. Austrianova’s scientists are experts in cell biology, GMP-grade cell products and encapsulation of living cells.

WHEREAS, as of the date hereof, Austrianova has developed a proprietary cell encapsulation technology to protect, isolate, store, and transport living cells, as well as oXering cell line development and GMP Manufacturing capabilities and expertise.

WHEREAS, Austrianova intends to contribute its intellectual property, knowhow, and resources as outlined below to Klothonova to achieve the purposes of this Agreement.

WHEREAS, AVAI will contribute all of the resources and capital required by Klothonova, Inc’s formation and operation for the next eighteen (18) months, not to exceed $1.5 million USD in capital and its resources in exchange for the common stock of Klothonova. AVAI will use its best eXorts to assist in arranging additional funding as needed, as described in this Agreement, at no cost to Austrianova.

WHEREAS, the ownership of Klothonova shall be 50% AVAI and 50%

Austrianova (each a “Member” and together, the Members)

WHEREAS, the company will be governed and operated pursuant to the terms of a limited liability company agreement.

NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein, the receipt and adequacy of which are hereby acknowledged, the Parties agree as follows:

1.1.         “A9iliate” means any Person, other than Klothonova, that: (a) is controlled by, controls, or is under common control with a Party (collectively, a “Controlled Person”); or (b) is controlled by, controls, or is under common control with any such Controlled Person, in each case for so long as such control continues.

1.2.         “Annual Plan” means a business operations plan detailing Klothonova’s goals and procedures for technical, financial, and administrative activities for Klothonova’s next succeeding fiscal year, as approved each year and revised from time to time by the Board.

1.3.         “Applicable Law” means, as to any Person, any statute, law, rule, regulation, directive, treaty, judgment, order, decree, or injunction of any Governmental Authority that is applicable to or binding upon such Person or any of its properties.

1.4.         “Articles” means the articles of incorporation of Klothonova substantially in the form attached hereto (Exhibit B - to be added upon formation of Klothonova), as amended from time to time.

1.5.         “Austrianova Background IP” means licenses, patents, and intellectual property data, technology and Know How held, owned, managed and controlled by Austrianova (whether patented / patentable or not) including but not limited to licensed technology from any third party that are essential for the Manufacturing of the Klotho Product.

1.6.         “Austrianova New IP” shall mean and include all Know-How, invented or developed during the Term solely by or on behalf of Austrianova or its Affiliates while performing activities under this Agreement, including assays, specifications, diagrams, technology, Manufacturing process descriptions, protocols, copies or samples of relevant documentation, materials, and other written know-how and other allied data related to the formulation, Manufacture, Development of the Klotho Product. These may lead to new Intellectual Property rights (whether patentable or not) and trade secrets to the benefit of Austrianova.

1.7.         “Austrianova Information” means all data and information related to or comprised in Intellectual Property, as well as other proprietary or confidential information in relation to Austrianova’s Manufacturing processes, technology and know-how which is owned or controlled by Austrianova or their A[iliates.

1.8.         “Background IP” means all Intellectual Property, results, data, inventions and information (i) owned by either Party (or owned by a Third Party licensor but licensed to a Party with the right to disclose / sub-license) prior to the date of the relevant Services, or (ii) developed by either Party during the Term independently of the Services and without the use of or reliance upon the other Party’s Intellectual Property or Confidential Information.

1.9.         “Board” means the board of directors of Klothonova.

1.10.     “Business” means the business of Klothonova as described in Section 2, as amended from time to time.

1.11.     “Business Day” means Monday to Friday exclusive of any public, national holiday in Singapore or in the United States.

1.12.     “Closing Date” is defined in Section 3.2(a).

1.13.     “Corporations Code” means the Nevada Revised Statutes, Chapter 78 et seq. as amended and in e[ect from time to time.

1.14.     “Company” is defined in Section 3.1.

1.15.     “Company Interest” means, as to any Person, the percentage interest of the total capital stock of Klothonova represented by the Securities then held by such Person divided by all then outstanding Securities (on an as converted to Common Stock basis and, to the extent warrants or options to purchase stock have vested, as exercised for Common Stock basis).

1.16.     “Confidential Information” is defined in Section 5. 1 (a).

1.17.     “Common Stock” means Common Stock of Klothonova as authorized by the Memorandum.

1.18.     “Director” means a director of Klothonova with the powers and duties as specified in the Corporations Code and the Articles.

1.19.     “Disclosing Party” is defined in Section 5.1 (a).

1.20.     “E9ective Date” means the date of this Agreement.

1.21.     “Establishment Date” is defined in Section 3.1.

1.22.     “Klotho Product” means a stable Klotho overexpressing cell line and the same incorporated into Cell-in-a-Box^® and/or any other drug substance and/or drug product, manufactured by Austrianova, using Austrianova Background IP, Austrianova Information, and all other requisite allied data.

1.23.     “Klothonova New IP” means new Intellectual Property created by the two Parties jointly and that is not attributable as an extension of Austrianova Background IP (Austrianova New IP)

1.24.     “Force Majeure” means causes beyond the control of either of the Parties, that prevents any of the Parties from performing its obligations assumed in this Agreement, including but not limited to, acts of God like floods, earthquakes, cyclones, unusually extreme weather etc.; acts, regulations, action, inaction, orders, restrictions, embargoes, laws or restrictions of central and/or state government, national or regional emergency, terrorism, war, civil commotion, destruction of production facilities or materials by fire, earthquake or storm, labour disturbances, epidemic, pandemic (and failure of public utilities or common carriers and the like.

1.25.     “Governmental Authority” means any domestic or foreign government, governmental authority, court, tribunal, agency or other regulatory, administrative or judicial agency, commission or organization, and any subdivision, branch or department of any of the foregoing.

1.26.     “Intellectual Property” (or “IP”) means Know-How, Patent Rights, trademarks, service marks, trade names, design rights, copyright (including rights in computer software) and any similar or equivalent rights or property or forms of protection in any part of the world, whether registered or not, together with the right to apply for the registration of any such rights.

1.27.     “Memorandum” means the memorandum of association of Klothonova substantially in the form of the attached Exhibit C (to be added on formation of Klothonova), as amended from time to time.

1.28.     “Party” and “Parties” are defined in the opening paragraph of this Agreement.

1.29.     “Person” means a natural individual, Governmental Authority, partnership, firm, corporation, or other business association.

1.30.     “Purpose” means to develop, use, and commercialize treatments for Alzheimer’s disease, heart disease, cancer, kidney disease, and for other age-related conditions, as well as for promoting longevity based on overexpression of the Klotho protein.

1.31.     “Receiving Party” is defined in Section 5.1(a).

1.32.     “Securities” means all outstanding Common Stock, and any other equity securities of Klothonova or instruments exercisable for or convertible into Common Stock.

1.33.     “Territory” means the world.

1.34.     “Term” is defined in Section 7.1.

1.35.     "Third Party” means any Person other than a Party or an A[iliate of either Party to this Agreement.

1.36.     “Transaction Documents” means this Agreement, the Articles and the Memorandum, and their related documents.

2.1.         The Parties hereby ratify to associate themselves in a joint venture relationship which shall have as its Purpose: (a) developing, maintaining, and supporting treatments, exclusively using encapsulated Klotho-producing cells, for various medical conditions (b) the principal indications will be Alzheimer’s disease, heart disease, cancer, kidney disease, and other age-related conditions, as well as for promoting longevity (c) the company shall account for each treatment program (which will be defined by the Board) separately.

3.1.         Establishment. The Parties agree that the joint venture contemplated by this Agreement shall be carried out exclusively through Klothonova, which will be established in accordance with the License Agreement to support the Purpose.

3.2.         Services and Duties; Licenses.

3.3.         Capitalization and Further Capitalization.

3.4.         Financial Assistance.

Each Party shall at all times have the preemptive right to purchase Common Stock or other equity interests as set forth in the Articles. The preemptive rights granted pursuant to this Section 3.4 shall cease to be of any further force or e[ect upon the closing of an initial public o[ering.

3.5.         Breach of Responsibilities

a)      In the event that any Party fails to fulfill its obligations as specified in Section 4 of this Agreement, and such failure persists for a period of fifteen (15) days following the receipt of written notice of the default from another Party detailing the default, then, after a ninety-day cure period, the breaching Party's ownership interest in Klothonova shall be diluted by an amount equivalent to the estimated financial harm resulting from the breach.

b)      In the event of a dispute regarding the calculation of the financial damages stemming from the breach, the Parties hereby agree to engage an impartial third-party mediator to assess and determine the extent of the harm incurred.

The Board will have ultimate responsibility for governance of Klothonova. In the event of a deadlock in decision-making at the Board level, the Parties agree to appoint an independent third-party mediator to cast a tie-breaking vote or propose alternative mechanisms to resolve the deadlock. Klothonova’s Chief Executive O[icer shall be Kenn Kerr who shall have the authority to operate the Business within parameters defined in this Agreement. Walter H. Günzburg, Ph.D., will initially serve as Chairman of the Board

4.3.        Removal; Reappointment of Directors. Any Director may be removed for cause in accordance with Applicable Law. In addition, each Party having the right to appoint a Director pursuant to this Section 4 shall also have the right, in its sole discretion, to remove such Director at any time, e[ective upon delivery of written notice to Klothonova, the Director to be removed and to the other Parties.In the case of a vacancy in the o[ice of a Director for any reason (including removal pursuant to the preceding sentence), the vacancy shall be filled by the Party that appointed the Director in question.

4.6.        Other O9icers. In addition to both the Chairman of the Board and The Chief Executive O[icer, senior management of Klothonova will consist of such other o[icers as are deemed to be necessary or appropriate by the Board.

4.10.    Day-to-Day Management

AVAI and Austrianova shall co-manage the day-to-day operations of the Business, including providing management support and personnel with respect to operations, accounting and finance, human resources, negotiating and e[ecting the expansion of the Business, and arranging for the funding of the capital needs of the Business by itself and through third parties. These costs will be invoiced to Klothonova by AVAI and Austrianova respectively. Majority management input into the various areas will be according to the following table:

(R stands for: “Responsible”, a full RACI chart may be developed later)

4.11.    Steering Committees. At the direction of, and upon approval by, the Board, Steering Committees may be formed to make decisions by topic: such as development, manufacturing/supply, human studies, commercialization,

4.12.    Price Consideration: The price consideration payable by Klothonova to Austrianova relative to IP licenses, service agreements and Manufacturing, invoices and supply of the Klotho Product shall be payable in US dollars (USD) at respectively Austrianova’s or AVAI’s designated bank account.

4.13.    Invoices: Each Party supplying products or services (“Supplying Party”) shall issue an invoice to Klothonova, for the payment of Klotho Product and/or services delivered in respect of the other Agreements

4.14.    Payment Period for Klotho Product and Services: Klothonova shall pay all invoices for Klotho Product and services within thirty (30) days unless stated otherwise in the invoice. The payment period begins on the date of receipt of the invoice by Klothonova. Any dispute on the invoice submitted shall be reported within seven (7) Business Days from the date of receipt of the invoice by Klothonova. In case no such concern is received from Klothonova within the given timeline, then such invoice will be deemed accepted by Klothonova. Klothonova shall make all the payments for the non-disputed invoices, to the Supplying Party as per the payment period agreed in this clause.

4.15.    Taxes. The amounts payable by one Party (the "Paying Party") to the other Party (the "Payee Party") pursuant to this Agreement (each, a "Payment") shall be paid free and clear of any and all taxes, except for any withholding taxes required by Applicable Law. Except as provided in this Section, the Payee Party shall be solely responsible for paying any and all taxes on income (other than withholding taxes required by Applicable Law to be deducted from Payments and remitted by the Paying Party), excluding applicable local taxes levied on account of, or measured in whole or in part by reference to, any Payments it receives.

4.16.    The Paying Party shall deduct or withhold from the Payments any taxes that is required by Applicable Law to deduct or withhold. Notwithstanding the foregoing, if the Payee Party is entitled under any applicable Tax treaty to a reduction of rate of, or the elimination of, applicable withholding Tax, it may deliver to the Paying Party or the appropriate Governmental Authority (with the assistance of the Paying Party to the extent that this is reasonably required and is requested in writing) the prescribed forms necessary to reduce the applicable rate of withholding or to relieve the Paying Party of its obligation to withhold such Tax and the Paying Party shall apply the reduced rate of withholding or dispense with withholding, as the case may be; provided that the Paying Party has received evidence of the Payee Party's delivery of all applicable forms (and, if necessary, its receipt of appropriate governmental authorization) at least fifteen (15) days prior to the time that the Payments are due.

4.17.    If, in accordance with the foregoing, the Paying Party withholds any amount, it shall pay to the Payee Party the balance when due, make timely payment to the proper Governmental Authority of the withheld amount and promptly send to the Payee Party necessary certificates as issued by the Governmental Authorities for such payment along with the relevant withholding tax certificates. The Parties will cooperate and use reasonable legal e[orts to reduce, mitigate, or eliminate adverse tax consequences.

4.18.    Dividends. The company shall account for each treatment program separately. The Board will define the programs. Profit generated from each treatment program will be returned to the Parties according to their Shareholding in the form of Dividends. Such Dividends will be paid out at least annually.

5.1.        Confidentiality.

a)      The Parties recognize that, in connection with the performance of this Agreement, each Party (in such capacity, the “Disclosing Party”) may disclose “Confidential Information” (as defined below) to the other Party (the “Receiving Party”). For purposes of this Agreement, the term “Confidential Information” means (i) proprietary information (whether owned by the Disclosing Party or a third party to whom the Disclosing Party owes a non-disclosure obligation) regarding the Disclosing Party’s business or (ii) information which is marked as confidential at the time of disclosure to the Receiving Party, or if in oral form, is identified as confidential at the time of oral disclosure and reduced in writing or other tangible (including electronic) form including a prominent confidentiality notice and delivered to the Receiving Party within 10 days of disclosure or technical information including but not limited to source code, documents, and product plans. “Confidential Information” shall not include information which: (A) was known to the Receiving Party at the time of the disclosure by the Disclosing Party; (B) has become publicly known through no wrongful act of the Receiving Party; (C) has rightfully been received by the Receiving Party from a third party without breach of this provision; or (D) has been independently developed by the Receiving Party without using any Confidential Information of the other Party. The Receiving Party agrees (x) not to use any such Confidential Information for any purpose other than in the performance of its obligations under this Agreement or any Transaction Document and (y) not to disclose any such Confidential Information, except (1) to its employees who are reasonably required to have the Confidential Information in connection herewith or with any of the other Transaction Documents, (2) to its agents, representatives, lawyers and other advisers that have a need to know such Confidential Information and (3) pursuant to, and to the extent of, a request or order by a Governmental Authority. The Receiving Party agrees to take all reasonable measures to protect the secrecy and confidentiality of, and avoid disclosure or unauthorized use of, the Disclosing Party’s Confidential Information.

b)      Each Party acknowledges and agrees that (i) its obligations under this Section 5.1 are necessary and reasonable to protect the other Party and its business, (ii) any violation of these provisions could cause irreparable injury to the other Party for which money damages would be inadequate, and (iii) as a result, the other Party shall be entitled to obtain injunctive relief against the threatened breach of the provisions of this Section 5.1 without the necessity of proving actual damages. The Parties agree that the remedies set forth in this Section 5.1 are in addition to and in no way preclude any other remedies or actions that may be available at law or under this Agreement.

5.2.        Confidentiality of Agreement, Publicity. Each Party agrees that the terms and conditions of this Agreement and the Transaction Documents shall be treated as confidential information and that no reference thereto shall be made thereto without the prior written consent of the other Party (which consent shall not be unreasonably withheld) except (a) as required by Applicable Law including,without limitation, by the U.S. Securities and Exchange Commission and other applicable countries’ Governmental Authorities, (b) to its accountants, banks, financing sources, lawyers and other professional advisors, provided that such parties undertake in writing (or are otherwise bound by rules of professional conduct) to keep such information strictly confidential, (c) in connection with the enforcement of this Agreement, (d) in connection with a merger, acquisition or proposed merger or acquisition, or (e) pursuant to joint press releases prepared in good faith. The Parties will consult with each other, in advance, with regard to the terms of all proposed press releases, public announcements and other public statements with respect to the transactions contemplated hereby.

Warranties of Avant. AVAI hereby represents and warrants to Klothonova that, as of the E[ective Date and as of the Closing Date, the following statements are and shall be true and correct:

a)      Organization. AVAI is a corporation duly organized and valid and has the corporate power and authority to enter into and perform this Agreement.

b)      Authorization. All corporate action on the part of AVAI necessary for the authorization, execution, and delivery of this Agreement and for the performance of all of its obligations hereunder and thereunder has been taken, and this Agreement when fully executed and delivered, shall each constitute a valid, legally binding and enforceable obligation of AVAI

c)       Government and Other Consents. Other than any licenses, permits, certifications or authorizations which may be required in connection with the Business, as to which AVAI makes no representation, no consent, authorization, license, permit, registration or approval of, or exemption or other action by, any Governmental Authority, or any other Person, is required in connection with AVAIs execution, delivery and performance of this Agreement, or if any such consent is required, AVAI has satisfied the applicable requirements.

d)      E9ect of Agreement. AVAI’s execution, delivery and performance of this Agreement will not (i) violate the Articles of Incorporation of AVAI or any provision of Applicable Law, (ii) violate any judgment, order, writ, injunction or decree of any court applicable to AVAI, (iii) have any e[ect on the compliance of AVAI with any applicable licenses, permits or authorizations which would materially and adversely a[ect AVAI, (iv) result in the breach of, give rise to a right of termination, cancellation or acceleration of any obligation with respect to (presently or with the passage of time), or otherwise be in conflict with any term of, or a[ect the validity or enforceability of, any agreement or other commitment to which AVAI is a party and which would materially and adversely a[ect AVAI, or (v) result in the creation of any lien, pledge, mortgage, claim, charge or encumbrance upon any assets of AVAI; provide, however, that regulatory approval may be required in connection with conducting the Business and AVAI makes no representation with respect to any such approvals.

e)      Litigation. There are no actions, suits or proceedings pending or, to AVAI’s knowledge, threatened, against AVAI before any Governmental authority which question AVAIs right to enter into or perform this Agreement, or which question the validity of this Agreement or any of the other Transaction Documents.

6.2 Warranties of Klothonova. Upon formation, Klothonova will represent and warrant to AVAI and Austrianova that, as of the E[ective Date and as of the Closing Date, the following statements are and shall be true and correct:

a)      Organization. Klothonova is a corporation duly organized and validly existing under the laws of Nevada. Klothonova has the corporate power and authority to enter into and perform this Agreement.

b)      Authorization. All corporate action on the part of Klothonova necessary for the authorization, execution, and delivery of this Agreement and for the performance of all of its obligations hereunder and thereunder has been taken, and this Agreement when fully executed and delivered, shall each constitute a valid, legally binding and enforceable obligation of Klothonova.

c)       Government and Other Consents. Other than any licenses, permits or authorizations which may be required in connection with the Business, as to which Klothonova makes no representation, no consent, authorization, license, permit, registration or approval of, or exemption or other action by, any Governmental Authority, or any other Person, is required in connection with Klothonova execution, delivery and performance of this Agreement, or if any such consent is required, Klothonova has satisfied any applicable requirements.

d)      E9ect of Agreement. Klothonova’s execution, delivery and performance of this Agreement will not (i) violate the Certificate of Incorporation of Klothonova or any provision of Applicable Law, (ii) violate any judgment, order, writ, injunction or decree of any court applicable to Klothonova, (iii) have any e[ect on the compliance of Klothonova with any applicable licenses, permits or authorizations which would materially and adversely a[ect Klothonova, (iv) result in the breach of, give rise to a right of termination, cancellation or acceleration of any obligation with respect to (presently or with the passage of time), or otherwise be in conflict with, any term of, or a[ect the validity or enforceability of any agreement or other commitment to which Klothonova is a party and which would materially and adversely a[ect Klothonova, or (v) result in the creation of any lien, pledge, mortgage, claim, charge or encumbrance upon any assets of Klothonova ; provided, however, that regulatory approvals may be required in connection with conducting the Business and Klothonova makes no representation with respect to any such approvals.

e)      Litigation. There are no actions, suits or proceedings pending or, to Klothonova’s knowledge, threatened, against Klothonova before any Governmental Authority which question Klothonova‘s right to enter into or perform this Agreement, or which question the validity of this Agreement or any of the other Transaction Documents.

a)      By any Party, provided at least ninety (90) days before renewal

b)      Upon the mutual written agreement of the Parties.

c)       By any Party, e[ective after a ninety-day cure period, upon written notice to the other Party, if the other Party breaches any material provision of this Agreement (except for those in Section 4 of this agreement pertaining to Operations and Management) or of any of the other Transaction Documents and such breach continues for a period of fifteen (15) days after the delivery of written notice of the default, describing the default in reasonable detail.

d)      By any Party, e[ective immediately upon written notice to the other Party, in the event that the other Party is dissolved, liquidated or declared bankrupt, or a voluntary or involuntary bankruptcy filing is made by such Party.

e)      Immediately upon lack of funding of Klothonova operations of up to $1.5 million as equity by AVAI, or later in the case of failure to find further needed investment.

f)       For Change of Control: Austrianova shall have the right, in its sole discretion to terminate this Agreement by a written notice of thirty (30) days to AVAI, in the event AVAI undergoes a change of control event. AVAI shall have the right, in its sole discretion to terminate this Agreement by a written notice of thirty (30) days to Austrianova, in the event Austrianova undergoes a change of control event.

g)      For Force Majeure event: if Austrianova is unable to perform its obligations for a period of more than sixty (60) days hereunder due to conditions within the scope of Force Majeure, then Austrianova shall have the right to terminate this Agreement by giving Klothonova a prior written notice of thirty (30) days.

Subject to restrictions set forth in any financing document entered into by Klothonova, upon completion of each Company’s business venture, Klothonova shall distribute its available cash (net cash generated from sale of the business venture and/or its units less disbursements and appropriate reserves), to the Parties based on their relative equity interest in Klothonova.

Klothonova shall indemnify and hold harmless its directors, officers, to the fullest extent permitted by law, from and against any and all liabilities and damages (including legal expenses) imposed on or incurred by them in any way relating to, or arising out of, their services to Klothonova, but not including costs in connection with a dispute(s) between the parties to this Agreement. Klothonova shall purchase an insurance policy providing directors’ and officers’ liability insurance.

UK using the English language, and in accordance with the rules of the UK Arbitration Act 2025. The arbitrator(s) shall have the authority to grant specific performance, and to allocate between the Parties the costs of arbitration in such equitable manner as the arbitrator(s) may determine. The prevailing Party in the arbitration shall be entitled to receive reimbursement of its reasonable expenses incurred in connection therewith. Judgment upon the award so rendered may be entered in any court having jurisdiction or application may be made to such court for judicial acceptance of any award and an order of enforcement, as the case may be. Notwithstanding the foregoing, either Party shall have the right to institute a legal action in a court of proper jurisdiction for injunctive relief and/or a decree for specific performance pending final settlement by arbitration

If to AVAI:

AVANT TECHNOLOGIES INC (AVAI): Attention: Chris Winter

5348 Vegas Drive

Las Vegas, Nevada 89108, USA

O +1 702.509.1747 | F +1 702.872.2060| M +1 770.833.6677

Email: chris@avanttechnologies.com

If to Klothonova:

KLOTHONOVA Inc., Attention: Kenn Kerr

5348 Vegas Drive

Las Vegas, Nevada 89108, USA

O +1 702.509.1747 | F +1 702.872.2060 | M +1 646.397.4020

Email: kkerr@avanttechnologies.com

If to Austrianova:

SGAustria Pte Ltd, Attention: Brian Salmons

2 Intnl. Business Park, The Strategy #09-04,

Singapore 609930, Singapore

O +65 6268.5077 | F +1 618.348.1110| M +65 9108.6741

Email: salmons@sgaustria.com

or to such other address or facsimile number as a Party may have specified to the other Party in writing delivered in accordance with this Section 11.2.